RxDoctor Payments Data

Kamran Riaz, MD

Cornea and External Diseases Specialist · Oklahoma City, OKNPI 1326276965

Payments from drug & device makers

$237,893in general payments, 2019–2025

Across 234 payments — averaging $1016.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$148K
  • Novartis$32K
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$32K
  • Glaukos Corporation$8K
  • AbbVie$7K
  • Carl Zeiss Meditec, Inc.$3K
  • plus $7K from 16 others

What the payments were for

  • Consulting fees$53,65927%
  • Speaking & faculty fees$122,37562%
  • Travel & lodging$13,8407%
  • Food & beverage$6,6943%
  • Education$1,5001%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few cornea and external diseases specialist providers in Oklahomato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$332,430
Medicare patients
551
Services billed
1,717

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MieboPerfluorohexyloctane/Pf36$31,059
Prednisolone Acetate534$22,513
RestasisCyclosporine23$14,473
ValacyclovirValacyclovir Hcl211$11,654
EysuvisLoteprednol Etabonate14$9,817
ZirganGanciclovir11$9,588
Ketorolac Tromethamine221$6,827
MoxifloxacinMoxifloxacin Hcl265$6,320
Fluorometholone85$5,869
Bromfenac Sodium25$5,247
Lotemax SmLoteprednol Etabonate18$5,080
Loteprednol Etabonate26$3,478
CombiganBrimonidine Tartrate/Timolol13$2,811
Doxycycline Monohydrate97$2,018
Brimonidine Tartrate80$1,878

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Miebo, Zirgan$147,925$40,64747 claims
AbbVieRestasis, Combigan$7,484$17,28436 claims
Kala Pharmaceuticals, Inc.Eysuvis$33$9,81714 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm, Loteprednol Etabonate$32,072$8,55744 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few cornea and external diseases specialist providers in Oklahomaon file to place this against a meaningful peer group, so we don't.

Other cornea and external diseases specialist in Oklahoma City

Where these figures come from

Is this you, or does something look wrong? →